Restoring function in failing hearts: The effects of beta blockers

American Journal of Medicine

Volumn 104, Issue 2, 1998, Pages 163-169

  Eichhorn, Eric J ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CARVEDILOL; CYCLIC AMP; DIGOXIN; INOTROPIC AGENT; METOPROLOL; PROPRANOLOL; VASODILATOR AGENT;

ADRENERGIC SYSTEM; CONGESTIVE HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART VENTRICLE REMODELING; HEMODYNAMICS; MORTALITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; VENTRICULAR FUNCTION, LEFT;

EID: 0032006640     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00171-X     Document Type: Review

References (87)

1. 1. Eichhorn EJ, Bristow MR. Medical therapy can improve the biologic properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation. 1996;94:2285-2296.
2. 2. Packer M. How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. Am J Cardiol. 1993;71:3C-11C.
3. 3. Packer M, Narahara KA, Elkayam U, et al, and the Principal Investigators of the REFLECT Study. Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. J Am Coll Cardiol. 1993;22:65-72.
4. 4. The German and Austrian Xamoterol Group. Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. Lancet. 1988;1:489-493.
5. 5. DiBianco R, Shabetai R, Kostuk W, et al. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. NEJM. 1989;320:677-683.
6. 6. Monrad ES, Baim DS, Smith HS, Lanoue AS. Milrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure. Circulation. 1986;73(suppl III):III-168-III-174.
7. 7. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet. 1990;336:1-6.
8. 8. Packer M, Carver JR, Chesebro JH, et al, and the PROMISE Investigators. Effect of milrinone on mortality in severe chronic heart failure. The prospective randomized milrinone survival evaluation (PROMISE). NEJM. 1991;325:1468-1475.
9. 9. Packer M, Rouleau J, Swedberg K, et al, and the PROFILE Investigators and Coordinators. Effect of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE study. Circulation. 1993;88(suppl I):I-301. Abstract.
10. 10. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epogrostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997;134:44-54.
11. 11. Dies F, Krell MJ, Whitlow P, et al. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure. Circulation. 1986;74(suppl II):II-38. Abstract.
12. 12. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. NEJM. 1986;314: 1547-1552.
13. 13. Katz A. Potential deleterious effects of inotropic agents in the therapy of chronic heart failure. Circulation. 1986;73(suppl III):III-184-III-190.
14. 14. Lee JC, Downing SE. Cyclic AMP and the pathogenesis of myocardial injury. Res Commun Chem Pathol Pharmacol. 1980;27:305-318.
15. 15. Martorana PA. The role of cyclic AMP in isoprenaline-induced cardiac necroses in the rat. J Pharm Pharmacol. 1971;23:200-203.
16. 16. Packer M, Francis GS, Abrams J, et al. Oral milrinone increases the risk of sudden death in severe chronic heart failure: the PROMISE trial. Circulation. 1991;84:II-310. Abstract.
17. 17. Kessler P, Packer M, Medina N, Yushak M. Long-term hemodynamic and clinical responses to flosequinan, a new once-daily balanced direct-acting vasodilator, in severe heart failure. Circulation. 1986;II-509. Abstract.
18. 18. Yui Y, Nakajima H, Kawai C, Murakami T. Prostacyclin therapy in patients with congestive heart failure. Am J Cardiol. 1982;50:320-324.
19. 19. Packer M, Lee WH, Kessler PD, et al. Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure. Circulation. 1987;75(suppl IV):IV-80-92.
20. 20. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20:248-254.
21. 21. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic β-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J. 1975;37:1022-1036.
22. 22. Eichhorn EJ. The paradox of β-adrenergic blockade for the management of congestive heart failure. Am J Med. 1992;92:527-538.
23. 23. Eichhorn EJ. Do β-blockers have a role in patients with congestive heart failure? Cardiol Clin. 1994;12:133-142.
24. 24. Eichhorn EJ, Hjalmarson Å. β-blocker treatment for chronic heart failure: the Frog Prince. Circulation. 1994;90:2153-2156.
25. 25. Doughty RN, MacMahon S, Sharpe N. Beta-blockers in heart failure: promising or proved? J Am Coll Cardiol. 1994;23:814-821.
26. 26. Engelmeier RS, O'Connell JB, Walsh R, et al. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation. 1985;72:536-546.
27. 27. Eichhorn EJ, Bedotto JB, Malloy CR, et al. Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure: improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation. 1990;82:473-483.
28. 28. Waagstein, F, Caidahl K, Wallentin I, et al. Long-term β-blockade in dilated cardiomyopathy: effects of short-and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation. 1989;80:551-563.
29. 29. Heilbrunn SM, Shah P, Bristow MR, et al. Increased β-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation. 1989;79:483-490.
30. 30. Eichhorn EJ, Heesch CM, Barnett JH, et al. Effect of metoprolol on myocardial function and energetics in patients with non-ischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 1994;24:1310-1320.
31. 31. Gilbert EM, Anderson JL, Deitchman D, et al. Chronic β-blocker-vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med. 1990;88:223-229.
32. 32. Pollock SG, Lytash J, Tedesco C, et al. Usefulness of bucindolol in congestive heart failure. Am J Cardiol. 1990;66:603-607.
33. 33. Woodley SL, Gilbert EM, Anderson JL, et al. β-blockade with bucindolol in heart failure due to ischemic vs idiopathic dilated cardiomyopathy. Circulation. 1991;84:2426-2441.
34. 34. Metra M, Nardi M, Giubbini R, DeiCas L. Effects of short-and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1994;24:1678-1687.
35. 35. Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure; a double-blind randomized study. J Am Coll Cardiol. 1995;25:1225-1231.
36. 36. Waagstein F, Bristow MR, Swedberg, et al, for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993;342:1441-1446.
37. 37. Bristow MR, O'Connell JB, Gilbert EM, et al, for the Bucindolol Investigators. Dose-response of chronic β-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation. 1994;89:1632-1642.
38. 38. Wisenbaugh T, Katz I, Davis J, et al. Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol. 1993;21:1094-1100.
39. 39. Paolisso G, Gambardella A, Marrazzo G, et al. Metabolic and cardiovascular benefits deriving from β-adrenergic blockade in chronic congestive heart failure. Am Heart J. 1992;123:103-110.
40. 40. Krum H, Sackner-Bernstein J, Goldsmith RL, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation. 1995;92: 1499-1506.
41. 41. Fisher ML, Gottlieb SS, Plotnick GD, et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol. 1994;23:943-950.
42. 42. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-β-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation. 1995;92:212-218.
43. 43. Hall SA, Cigarroa CG, Marcoux L, et al. Time course of improvement in left ventricular function, mass, and geometry in patients with congestive heart failure treated with β-adrenergic blockade. J Am Coll Cardiol. 1995;25:1154-1161.
44. 44. Bristow MR. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am J Cardiol. 1993;71:12C-22C.
45. 45. Eichhorn EJ, Bristow MR. Practical guidelines for initiation of β-adrenergic blockade in patients with chronic heart failure. Am J Cardiol. 1997;79:794-798.
46. 46. Haber HL, Simek CL, Gimple LW, et al. Why do patients with congestive heart failure tolerate the initiation of β-blocker therapy? Circulation. 1993;88:1610-1619.
47. 47. Di Lenarda A, Gilbert EM, Olsen SL, et al. Acute hemodynamic effects of carvedilol vs metoprolol in idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1991;17:142A. Abstract.
48. 48. Talwar KK, Bhargava B, Upasani PT, et al. Hemodynamic predictors of early intolerance and long-term effects of propranolol in dilated cardiomyopathy. J Cardiac Failure. 1996;2:273-277.
49. 49. Packer M, Bristow MR, Cohn JN, et al, for the U.S. Carvedilol Heart Failure Study Group. Effect of carvedilol on morbidity and mortality in chronic heart failure. NEJM. 1996;334:1349-1355.
50. 50. Katz A. Cellular mechanisms in congestive heart failure. Am J Cardiol. 1988;62:3A-8A.
51. 51. Katz A. The cardiomyopathy of overload: an unnatural growth response in the hypertrophied heart. Ann Intern Med. 1994;121:363-371.
52. 52. Yamazaki T, Komuro I, Zou Y, et al. Norepinephrine induces the raf-1 kinase/mitogen-activated protein kinase cascade through both α1-and β-adrenoceptors. Circulation. 1997;95:1260-1268.
53. 53. Sadoshima J, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell. 1993;75:977-984.
54. 54. Komuro I, Kaida T, Shibazaki Y, et al. Stretching cardiac myocytes stimulates cell hypertrophy and specific gene expression in cultured rat cardiac myocytes: possible role of protein kinase C activation. J Biol Chem. 1991;266:1265-1268.
55. 55. Schieffer B, Paxton WG, Marrero MB, Bernstein KE. Importance of tyrosine phosphorylation in angiotensin II type 1 receptor signaling. Hypertension. 1996;27(part 2):476-480.
56. 56. Yokoyama T, Nakano M, Bednarczyk JL, et al. Tumor necrosis factor-α provokes a hypertrophic growth response in adult cardiac myocytes. Circulation. 1997;95:1247-1252.
57. 57. Wollert KC, Taga T, Saito M, et al. Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy. Assembly of sarcomeric units in series via gp130/leukemia inhibitory factor receptor-dependent pathways. J Biol Chem. 1996;271:9535-9545.
58. 58. Arai M, Alpert NR, MacLennan DH, et al. Alterations in sarcoplasmic reticulum gene expression in human heart failure. Circ Res. 1993;72:463-469.
59. 59. Cory CR, McCutcheon LJ, O'Grady M, et al. Compensatory downregulation of myocardial Ca channel in SR from dogs with heart failure. Am J Physiol. 1993;264:H926-H937.
60. 60. Schwartz K, Carrie L, Mercadier J-J, et al. Molecular phenotype of the hypertrophied and failing myocardium. Circulation. 1993; 87(suppl VII):VII-5-VII-10.
61. 61. Schwartz K, Boheler KR, DeLaBastie D, et al. Switches in cardiac muscle gene expression as a result of pressure and volume overload. Am J Physiol. 1992;262:R364-R369.
62. 62. Lowes BD, Minobe WA, Abraham WT, et al. Downregulation of α-and upregulation of β-myosin heavy chain in intact, failing human ventricles. J Am Coll Cardiol. 1997;29(suppl A):423A. Abstract.
63. 63. Sabbah HN, Goldstein S. Ventricular remodeling: consequences and therapy. Eur Heart J. 1993;14(suppl C):24-29.
64. 64. Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest. 1975;56:56-64.
65. 65. Kono T, Sabbah HN, Rosman H, et al. Left ventricular shape is the primary determinant of functional mitral regurgitation in heart failure. J Am Coll Cardiol. 1992;20:1594-1598.
66. 66. Douglas PS, Morrow R, Ioli A, Reichek N. Left ventricular shape, afterload and survival in idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1989;13:311-315.
67. 67. Rahman MA, Hara K, Daly PA, et al. Reductions in muscle sympathetic nerve activity after long term metoprolol for dilated cardiomyopathy: preliminary observations. Br Heart J. 1995;74: 431-436.
68. 68. Eichhorn EJ, McGhie AI, Bedotto JB, et al. Effects of bucindolol on neurohormonal activation in congestive heart failure. Am J Cardiol. 1991;67:67-73.
69. 69. Mann DL, Kent RL, Parsons B, Cooper GIV. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992; 85:790-804.
70. 70. Franciosa JA, Wilen M, Ziesche S, Cohn JN. Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol. 1983; 51:831-836.
71. 71. Cintron C, Johnson G, Francis G, et al. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. Circulation. 1993;87(suppl VI):VI-17-VI-23.
72. 72. Tsutsui H, Spinale FG, Nagatsu M, et al. Effects of chronic β-adrenergic blockade on the left ventricular and cardiocyte abnormalities of chronic canine mitral regurgitation. J Clin Invest. 1994;93: 2639-2648.
73. 73. Fuleihan F, Matsumori A, Gwathmey JK. Effects of carteolol, a β-blocker, on mortality and left ventricular heart function in dilated cardiomyopathy. Circulation. 1993;88(suppl I):I-38. Abstract.
74. 74. Bristow MR, Gilbert EM, Abraham WT, et al. for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 1996;94:2807-2816.
75. 75. Bristow MR, Gilbert EM. Improvement in cardiac myocyte function by biological effects of medical therapy: a new concept in the treatment of heart failure. Eur Heart J. 1995;16(suppl F):20-31.
76. 76. Lowes BD, Gill EA, Rodriguez-Larrain J, et al. Carvedilol is associated with a reversal of remodeling in chronic heart failure. Circulation. 1996;94(suppl I):I-407. Abstract.
77. 77. Eichhorn EJ, Heesch CM, Risser RC, et al. Predictors of systolic and diastolic improvement in patients with dilated cardiomyopathy treated with metoprolol. J Am Coll Cardiol. 1995;25:154-162.
78. 78. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). NEJM. 1987;316:1429-1435.
79. 79. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. NEJM. 1991;325:293-302.
80. 80. Pfeffer M, Braunwald E, Moyé L, et al, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of survival and ventricular enlargement trial. NEJM. 1992; 327:669-677.
81. 81. Pfeffer MA, Lamas GA, Vaughan DE, et al. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. NEJM. 1988;319:80-86.
82. 82. Sharpe N, Smith H, Murphy J, et al. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition. Lancet. 1991;337:872-876.
83. 83. Konstam MA, Rousseau MF, Kronenberg MW, et al, for the SOLVD Investigators. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. Circulation. 1992;86:431-438.
84. 84. Greenberg B, Quinones MA, Koilpillai C, et al, for the SOLVD Investigators. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation. 1995;91:2573-2581.
85. 85. Francis GS, Cohn JN, Johnson G, et al, for the V-HeFT V A Cooperative Studies Group. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Circulation. 1993;87(suppl VI):VI-40-VI-48.
86. 86. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1994;90:1765-1773.
87. 87. The BEST Steering Committee. Design of the Beta-Blocker Evaluation Survival Trial (BEST). Am J Cardiol. 1995;75:1220-1223.